Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis

Strategy analysis


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • UK Healthcare System Overview

    $2,995.00

    Reform of the NHS is underway despite widespread controversy and opposition from physicians, and will necessitate a change in the way pharmaceutical companies work with key stakeholders.

    November 2, 2016
    Find out more
  • Colorectal Cancer KOL Interview – US

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for colorectal cancer. Disease stratifications by staging and expression profile of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Keytruda, Braftovi, Opdivo, Avastin (and bevacizumab biosimilars), Herceptin (and trastuzumab biosimilars), Lonsurf, and Erbitux.

    October 29, 2020
    Find out more
  • GLP-1 Pulse Survey

    $599.00

    This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

    August 25, 2014
    Find out more
  • Russia Generics and Biosimilars

    $2,995.00
    • Despite high volume uptake, generics still account for only a small proportion of the total market value in Russia, driven by a lack of incentives for generic substitution and the significant originator/generic price differential.
    November 3, 2016
    Find out more
  • Datamonitor Schizophrenia KOL Interview 2

    $599.00

    KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

    February 24, 2016
    Find out more
  • Precision Medicine and the Future of Healthcare

    $2,995.00

    Precision medicine is typically associated with the use of therapies that target particular disease-linked genetic mutations, identified via a diagnostic test.

    October 14, 2016
    Find out more
  • Key Potential Drug Launches in 2020

    $2,995.00

    As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2020.

    May 28, 2019
    Find out more
  • Russia Pharmaceutical Market Dynamics

    $2,995.00

    With the Russian economy recovering from the recession experienced in 2009, the pharmaceutical market has also returned to growth.

    November 2, 2016
    Find out more
  • Dyslipidemia KOL Insight Interview #1

    $599.00

    Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

    July 25, 2014
    Find out more
  • Treatment of VTE – EU KOL Interview

    $599.00

    This interview with an EU vascular physician explores the dynamics in the 5 major European markets regarding the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

    November 4, 2015
    Find out more
  • Chronic Neuropathic Pain Survey

    Chronic Neuropathic Pain KOL Survey

    $599.00

    Biomedtracker performed a 5-question survey of 30 United States neurologists who currently treat patients with chronic neuropathic pain and prescribe opioids to at least some of their patients with chronic neuropathic pain to gauge current use of adjuvants (TCAs, anti-convulsants, SNRIs, SSRIs, and NMDA receptor antagonists) and potential future use of cebranopadol and raxatrigine to treat chronic neuropathic pain.

    March 9, 2017
    Find out more
  • Datamonitor Healthcare Strategy: Gene Therapy Commercialization – Opportunities and Barriers

    $2,995.00

    Commercialization of modern-day gene therapies is now a reality. Next-generation modalities such as chimeric antigen receptor T-cell (CAR- T) therapies are fully in launch mode in the US, with final approvals having also occurred in the EU.

    October 25, 2018
    Find out more
  • Pharma’s Patient Centricity

    $2,995.00

    Patient centricity is the buzzword of this decade, and necessarily so: it either underpins, or is an inevitable result of, all the forces shaping today’s rapidly evolving healthcare landscape.

    October 17, 2016
    Find out more
  • 2015 Cancer Drug Pricing Surveys

    $799.00

    We performed two 5-question surveys of oncologists in the US to gauge the impact of cancer treatment costs on prescribed therapies.

    August 10, 2015
    Find out more
  • Argentina Regulatory Issues

    $2,995.00

    With a growing economy and 40 million inhabitants, Argentina is one of the most important emerging market destinations in South America.

    November 2, 2016
    Find out more
Page 22 of 23
Page 22 of 23«‹20212223›
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top